A17 (P346)Severe hypoglycaemia, cardiovascular outcomes and death: Experience from the ‘Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results’ (LEADER) trialS BAIN1, B Zinman2, SP Marso3, E Christiansen4, S Calanna4, S Rasmussen4, and JB Buse51School of Medicine, University of Swansea, Swansea, UK, 2Lunenfeld–Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada, 3Research Medical Center, Kansas City, Missouri, USA, 4Novo Nordisk A/S, Søborg, Denmark, 5University of North Carolina School of Medicine, Chapel Hill, North Carolina, USAAims: In the LEADER cardiovascular (CV) outcomes trial (N = 9,340; NCT01179048), the risk of both CV events and hypoglycaemia was reduced with liraglutide treatment vs placebo, when added to standard of care, in patients with Type 2 diabetes and high risk for CV disease. This post hoc analysis examines potential associations between severe hypoglycaemia and CV events and death.Methods: We analysed time to first major adverse cardiovascular event ([MACE] CV death, non‐fatal myocardial infarction or non‐fatal stroke), CV death and all‐cause death, comparing patients with/without severe hypoglycaemia, and adjusted for different periods of follow‐up and randomised treatment (time‐dependent covariate Cox regression).Results: A total of 267 patients experienced severe hypoglycaemia (liraglutide n = 114, placebo n = 153; rate ratio 0.69; 95% confidence interval [CI] 0.51 to
Diabetic Medicine – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera